Thirty patients were examined to test the hypothesis that a depletion of iron levels is associated with symptoms of akathisia. Fifteen akathisic patients were pair-matched with 15 non-akathisic patients. Plasma ferritin levels were significantly decreased in the akathisic patients, and there was a significant inverse correlation between plasma iron levels and akathisia rating. In addition, akathisia ratings were found to be correlated with a scale measuring symptoms of tardive dyskinesia. They were pair-matched with 15 patients by age, sex, length of illness, length of recent inpatient stay, and dose of neuroleptic medication. Patients on iron supplements, on nonsteroid anti-inflammatory drugs, on antacids, and cimetidine were excluded. Since the hypothesis was based on a presumptive interactive effect of neuroleptic medication and iron at the receptor level, patients receiving
A previous study conducted in Glasgow' reported significantly lower serum iron and percentage saturation and a higher total iron binding capacity in a group of chronic psychiatric patients with akathisia compared with matched controls. The authors also found a (non significant) correlation of -0-42 (Spearman's rho) between serum iron and akathisia rating. After the exclusion of an outlying value, there were no significant differences in ferritin levels between groups. The authors argued that akathisia might therefore be related to dopamine-D2 receptor hypofunction due to a relative deficit of serum and consequently brain iron. They suggested that, like the restless leg syndrome, akathisia might be amenable to iron supplement treatment. We felt that a replication study should be carried out for the following reasons: apart from the possibility of a false positive result due to small numbers (n = 13) They were pair-matched with 15 patients by age, sex, length of illness, length of recent inpatient stay, and dose of neuroleptic medication. Patients on iron supplements, on nonsteroid anti-inflammatory drugs, on antacids, and cimetidine were excluded. Since the hypothesis was based on a presumptive interactive effect of neuroleptic medication and iron at the receptor level, patients receiving the atypical neuroleptic oxypertine' were excluded from the study. Pre-menopausal females and patients with clinical or laboratory evidence of renal or hepatic failure, as well as patients with a history of organic brain damage and epilepsy were excluded.
All patients were treated with neuroleptic drugs with no change in dose over the previous month. The number of cigarettes smoked per day was recorded. Patients were assessed by two raters independently, using the Brief Psychiatric Rating Scale,4 the Hamilton Anxiety Scale,5 the Simpson and Angus Scale for drug induced Parkinsonism,6 the Abnormal Involuntary Movement Scale (AIMS),7 and an Akathisia Scale used in the previous study.' Venous blood samples (40 ml) were collected between 7 and 8 am on two consecutive days following an overnight fast and before breakfast. Samples were taken without tourniquet in the sitting position and collected in heparinised vacutainers. Samples were immediately separated using an MSE bench centrifuge at 3000 g for 10 minutes, then divided into 1 ml aliquots, frozen and stored at -20°C in plastic tubes until analysed. The analyses were performed in a single batch blind procedure. Per assay and patient, four samples were analysed, that is, two split-half samples for each of the two consecutive days. The assay procedures for plasma iron, transferrin-binding, and ferritin have been described in detail elsewhere.8 Data were analysed using the Aberdeen University mainframe computer and SPSSX.9 Ethical approval for the study was given by the Joint Ethical Committee of Grampian Health Board and the University of Aberdeen. Informed consent was obtained from all subjects.
Results
Means and standard deviations for the matching variables for akathisics and controls are given in table 1. There were no significant differences between groups for these variables. There was also no difference in the number of cigarettes smoked by patients in either group. The inter-rater reliability of total movement disorder scores was acceptable, with 95% confidence intervals for interrater differences within + / -2 scoring points.
There was no systematic relationship between inter-rater differences and average scores.'0 Average scores of both raters could therefore be used. Median scores and ranges of rating scales for akathisics and controls are given in ,vug/100 ml 0 lli I .o°o 1 2 3 4 5 6 7 8 9 10 Case No 11 12 13 14 15 dent variables. A repeated measures design was used with the within-subjects factors of group (akathisic versus non-akathisic), day (first or second), and split-half of sample (first or second). The effect of akathisia versus control was significant (p = 0 024) for serum ferritin only. No other single or interaction effect was significant for any of the other dependent variables. Figure 1 gives the average values for patients plotted in pairs. There was a significant product moment correlation coefficient of r = -0 49 (df = 13, p = 0 03) between Akathisia score and plasma iron in the akathisic group (fig 2) .
There was also a significant correlation between AIMS scores and akathisia scores (df = 28, p < 0-01). The closest fit (R2 = 0 56) was achieved by a quadratic regression equation: AIMS-Score = 1.5 + 0 3 x Akathisia Score + 0-01 x (Akathisia Score2). Akathisia scores were not correlated with dose of neuroleptic, with drug-induced Parkinsonism, or with anxiety scores. To achieve greater comparability between studies, the result of pairs with an akathisic patient with akathisia scores > 10 (n = 11)
were analysed separately.' The result of the MANOVA was similar to that for the whole group, with a significant group-effect (akathisic versus non-akathisic) for ferritin-levels (p = 0 008). The inverse correlation between plasma iron levels and akathisia scores in the akathisic group increased and therefore remained significant even for the smaller number (r = -0 55, df = 9, p = 0 04).
While Brown et al excluded patients with tardive dyskinesia and Parkinsonian symptoms, the patients in this study showed a range of severities for both syndromes (table   Total iron 
Discussion
This study broadly supports the notion that chronic akathisia in patients on long term neuroleptic treatment may be related to the depletion of iron stores. This is suggested by the significant reduction of plasma-ferritin levels in the akathisic group.2 We were also able to replicate the finding of a correlation between akathisia scores and iron levels. The care given in this study to the standardisation of blood sampling and to an assessment of the reliability of measures, together with the results of the previous study,' suggest that these findings are valid. As described by Brown et al,' dietary iron depletion has been found to mimic D-2 receptor blockade in a variety of animal models. In addition, iron depletion has been shown to lead to a reversible reduction of Bmax for 3H-Spiperone binding in caudate nucleus.'2 This would give a rationale for a causal explanation of the symptoms of akathisia by low iron levels.
We feel that the situation might be more complicated, as the patients examined in the two studies did not appear to have acute akathisia which occurs when neuroleptic medication is started or increased, but chronic "tardive" akathisia."3 Our patients, as well as those of Brown's, were on doses of neuroleptic Alternatively, and possibly in addition to the previous mechanisms, the catalytic effect of iron accumulated in globus pallidus and substantia nigra" 1 on H202 generated by enzymatic reactions in the basal ganglia could lead to the generation of free radicals and to lipid peroxidation of nigro-pallidal and striato-nigral GABA systems.'9 This could be responsible for the irreversible brain damage associated with some cases of tardive dyskinesia.
Some aspects of the above hypothesis are directly amenable to empirical testing in patients: for example, an examination of the relationship between iron status and tardive dyskinesia in patients would be of interest. The effect of neuroleptic medication on iron parameters during acute treatment, and its relationship with acute akathisia should be examined in a prospective study.
Finally, the time appears to be ripe for a controlled study of iron supplement treatment in chronic akathisia, although the failure to increase brain iron levels in rats by intravenous infusion of oxyferriscorbone20 is likely to temper excessive optimism. 
